Lilotomab Biosimilar - Research Grade

Human

CD37

>1mg/ml

IgG1 - kappa

CHO Cells

Otlertuzumab Biosimilar - Research Grade (ICH5172), Oxelumab Biosimilar - Research Grade (ICH5187), Ivicentamab Biosimilar - Research Grade (ICH5612), Naratuximab Biosimilar - Research Grade (ICH5698)

https://www.imgt.org/mAb-DB/

ICH3002

P11049

Blue ice

This product is an unconjugated, non-therapeutic recombinant analog of lilotomab, an anti-CD37 monoclonal antibody, supplied for research use only. It is a human IgG1/kappa antibody built to engage CD37 on the surface of normal and malignant B cells, and is not the clinical drug or a radioconjugate; it is intended as a naked (unlabelled) binder for laboratory work. The originator lilotomab is best known as the targeting antibody of the CD37-directed radioimmunoconjugate developed for B-cell non-Hodgkin lymphoma, where the cold antibody is also used as a pre-dose. In a research setting the unconjugated analog is useful as a defined anti-CD37 reagent for binding and specificity assays, flow-cytometry-based target detection, competition and epitope studies, as a positive or isotype-matched control, and as a starting antibody for antibody-drug-conjugate or radioimmunoconjugate development workflows. It is offered at research grade with low endotoxin (typically under 1 EU/mg, with ultra-low-endotoxin options under 0.5 EU/mg) and in bulk milligram-to-gram quantities suitable for assay development and preclinical characterization. Not for human or veterinary use. CD37 (UniProt P11049) is a member of the tetraspanin (transmembrane 4) superfamily, a heavily glycosylated cell-surface glycoprotein with four transmembrane domains and two extracellular loops. It is strongly and selectively expressed on mature B cells, with lower expression on other leukocytes, and is a structural component of tetraspanin-enriched microdomains that organize receptor clustering and signaling at the membrane. Through these interactions CD37 contributes to B-cell activation, adhesion and migration, survival/apoptotic signaling, and to germinal-center function and long-lived antibody responses; CD37-deficient mice show reduced IgG1 and impaired T-dependent antibody responses. CD37 is highly expressed on most B-cell non-Hodgkin lymphomas and its expression is independent of CD20-directed therapy, making it an attractive alternative antigen. It internalizes on antibody binding, supporting its use in conjugate-delivery strategies.

Tetraspanin-26, Tspan-26, Leukocyte antigen CD37

This monoclonal antibody was purified using Protein A

Sterile, preservative-free, solution in PBS. BSA and Azide free.

This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Functional Assays

This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Products are for research use only. Not for use in diagnostic or therapeutic procedures.

3-4 weeks